Recent News

• 09.04.2025 - SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
• 08.25.2025 - SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
• 08.13.2025 - SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.13.2025 - SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 05.28.2025 - SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
• 05.15.2025 - SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.15.2025 - SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.01.2025 - 8-K Current report
• 06.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.26.2025 - 8-K Current report
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]